BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29916922)

  • 1. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
    Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
    Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
    Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Internal and External Radiation Exposure of Caregivers of Patients With Pediatric Neuroblastoma Undergoing 131I Metaiodobenzylguanidine Therapy: A Prospective Pilot Study.
    Han S; Yoo SH; Koh KN; Lee JJ
    Clin Nucl Med; 2017 Apr; 42(4):271-274. PubMed ID: 28098666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
    Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
    Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
    Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
    J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
    Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
    J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
    Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
    Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
    Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
    Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.
    Chu BP; Horan C; Basu E; Dauer L; Williamson M; Carrasquillo JA; Pandit-Taskar N; Modak S
    Pediatr Blood Cancer; 2016 May; 63(5):801-7. PubMed ID: 26773712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
    Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
    Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
    Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
    Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.
    Turpin BK; Morris VR; Lemen L; Weiss BD; Gelfand MJ
    Health Phys; 2013 Feb; 104(2 Suppl 1):S43-6. PubMed ID: 23287519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
    Flower MA; Fielding SL
    Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.